Lifecore Biomedical PE ratio LFCR

Share price divided by earnings per share over the last twelve months, since 2012.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 146×; Dec 2024
10-year median: 30.4×
10-year range: 12.5× to 152×
Peer median: 11.3×

Lifecore Biomedical's PE ratio is not a meaningful number today: diluted EPS for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Dec 2024, at 146×.

On the days it had one over the last ten years, its median was 30.4×, from 12.5× in Jan 2019 to 152× in Dec 2024.

PE ratio over time

median 30.4×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	146×	19.0×	152×
2023	n/m a value too high to mean anything
2022	n/m a value too high to mean anything
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	42.6×	12.5×	43.3×
2018	14.1×	14.1×	44.8×
2017	36.0×	26.7×	38.1×
2016	n/m a value too high to mean anything
2015	23.0×	20.3×	23.0×
2014	22.5×	15.3×	22.5×
2013	14.1×	13.1×	20.2×
2012	17.8×	17.4×	23.4×

Against its peers

Companies in Drug Manufacturers - General nearest Lifecore Biomedical's size, closest first, today.

Company	PE ratio
LFCRLifecore Biomedical	n/m
NATRNatures Sunshine Products	12.0×
ARVNArvinas	45.6×
PBYIPuma Biotechnology	21.2×
IRWDIronwood Pharmaceuticals	4.5×
ZVRAZevra Therapeutics	10.5×
CRMDCorMedix	3.7×
COLLCollegium Pharmaceutical	18.5×
LFVNLifevantage	14.7×
ABUSArbutus Biopharma	5.4×
SPROSpero Therapeutics	10.1×
Peer median	11.3×

What the PE ratio tells you

Share price divided by earnings per share over the last twelve months. It is the price tag on a dollar of profit: 20× means you pay $20 for $1 of yearly earnings.

Blank while earnings are negative. A very low PE can mean the market expects profits to fall, so read it with growth and the company's own history.

More on Lifecore Biomedical

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.